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signaling from these resistant tumor cells resulted in an 
additional level of treatment resistance towards the 
combined treatment modality of MSAs and ionizing radiation 
in vivo. However, combined treatment of MSAs with clinically 
relevant mTOR-signaling- or VEGF-antagonists strongly re-
sensitized MSA-resistant tumors (lung and colon carcinoma 
models) to the corresponding MSA. Interestingly, a novel 
clinically relevant microtubule-destabilizing agent, which is 
still active in MSA-resistant tumors, successfully overcame 
MSA-resistance in the lung and colon carcinoma models, 
downregulated the HIF1-alpha related aggressive tumor 
phenotype and strongly sensitized for ionizing radiation 
(bolus and metronomic scheduling). 
 
Conclusion: These data demonstrate that the interaction 
between the tumor cell compartment and the tumor 
microenvironment strongly determines the tumor response to 
the combined treatment modality of ionizing radiation and 
microtubule interfering agents. A combined treatment 
modality of microtubule interfering agents with 
antiangiogenic agents is potent to overcome tumor cell-
linked MSA-resistance and should be considered as clinical 
strategy for MSA-refractory tumor entities alone and in 
combination with radiotherapy. 
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Purpose or Objective: We aimed to evaluate the 
pathological hypoxic and perfusion effects of Trastuzumab 
(T) and/or Cisplatin (C) in HER2+ oesophageal 
adenocarcinoma xenograft (OE19) which may potentially 
direct future clinical adjunctive therapy. 
 
Material and Methods: SCID mice (n=17) bearing 
subcutaneous OE19 tumours were treated with either (i) 
Cisplatin 4mg/kg once a week, (ii) Trastuzumab 20mg/kg 
twice a week or (iii) Cisplatin and Trastuzumab for 2 weeks. 
Intraperitoneal Pimonidazole (Pm), an exogenous hypoxic 
marker, and intravenous Hoechst 33342 (Ho), a perfusion 
marker, were injected 2 hours and 1 minute prior to tumour 
excision, respectively. Tumours were immediately snap-
frozen and 10μm frozen sections were obtained for 
immunofluorescence study. Following fixation, non-specific 
binding was blocked using 10% normal goat serum. The 
sections were then incubated overnight at 4°C with primary 
Pimonidazole FITC labelled mouse monoclonal antibody at 
1:25 concentration. Propidium iodide (PI) was used as a 
counterstain to highlight morphology. Tumour sections were 
scanned using different filters for Pm (green), Ho (blue) and 
PI (red) on a fluorescence microscope at x100 magnification 
(Figure 1).  
 
 
 
Image analysis was performed using the ImageJ software. 
Percentage areas stained with Pm (hypoxic fraction/HF) and 
Ho (perfusion fraction/PF) were derived and mean (%) ± SD 
are presented. Difference in the HF and PF between 
Trastuzumab (T) and non-Trastuzumab (NT) treated animals 
were analysed. 
 
Results: Overall, tumour periphery was better perfused in 
most tumours but there was no consistent hypoxic 
intratumoral spatial localisation. There was an inverse spatial 
relationship between Pm and Ho fluorescence in 10/17 
tumours, colocalisation in 3/17 and no relationship found in 4 
tumours. Trastuzumab-treated tumours (HF 38%±17) were 
less hypoxic compared to the NT group (HF 50%±13) and these 
tumours were also better perfused (PF: T 46%±25, NT 
39%±16). Cisplatin-treated tumours had the highest HF 
(50%±13) and lowest PF (39%±16) compared to Trastuzumab 
(HF 34%±13, PF 48%±26) and combination therapy (HF 
41%±21, PF 45%±27). 
 
Conclusion: Trastuzumab appeared to exert the predominant 
proangiogenic effect with improved perfusion and reduced 
intratumoral hypoxia, although these effects were diminished 
with combination therapy. These data suggest that the 
addition of hypoxia-modifying agents might be tested as an 
adjunctive therapy, particularly in those not eligible or fit for 
Trastuzumab therapy. 
 
Poster: Radiobiology track: Normal tissue effects: 
pathogenesis and treatment  
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Purpose or Objective: In radiotherapy of head and neck 
cancer the central nervous system is the dose limiting factor. 
Late side effects may occur which severely impair the 
patient’s quality of life. Thus, to improve the therapeutic 
ratio, radioprotective drugs receive increasing interest. In 
the optimal case, they could protect the normal central 
nervous system without influencing the tumor response to 
irradiation. A lot of studies using various approaches with 
e.g. melatonin, pentoxifylline, growth factors, Amifostine or 
Angiotensin converting enzymes inhibitors (ACEi) were 
performed focusing on mitigation or, ideally, on protection 
from late side effect in central nervous system (brain, optic 
nerve or spinal cord). 
 
Material and Methods: Within our study the impact of ACEi 
Ramipril on prevention from the late side effect radiation-
induced myelopathy (forelimb paresis grade II) was tested. 
The cervical spinal cord of female Sprague Dawley rats was 
irradiated with either 6 MeV photons or carbon ions (12C-ion) 
(a linear energy transfer (LET) of 45 keV/µm and a 6 cm 
spread-out Bragg Peak was used). Immediately after 
irradiation (RT) Ramipril (2 mg/kg/day) was given via the 
drinking water for 300 days. A total of four groups were used: 
(1) photon RT + Ramipril (n = 24), (2) photon RT only (n = 20), 
(3) 12C-ion RT + Ramipril (n = 20) and (4) 12C-ion RT only (n = 
20). For each group a complete dose-response curve after 
single dose irradiation was established and TD50-values (dose 
at 50% complication probability) were determined for the 
development of paresis grade II within 300 days. 
 
Results: Preliminary analysis of the data shows no marked 
shift of the TD50-values related to administration of Ramipril 
after 12C-ion or photon RT, however, a prolongation of 
latency time for both irradiation modalities was found. At a 
dose level of 21 Gy the minimum latency time after 12C-ion 
RT was 160 d compared to 191 d after 12C-ion RT + Ramipril 
administration. Whereas, at a dose level of 26 Gy the 
minimum latency time after photon RT was 191 d compared 
to 225 d after photon RT + Ramipril administration. Overall 
the latency time after 12C-ion RT was shorter compared to 
photon RT. 
 
Conclusion: Ramipril administration after 12C-ion or photon 
RT exhibits a prolongated latency time. However, to find an 
ideal radiomitigator further examinations of the underlying 
pathological mechanisms leading to radiation-induced 
myelopathy are necessary. Additionally, since it is unclear 
how Ramipril interfers the pathological mechanism(s) of 
radiation-induced damage, it is important to understand the 
underlying mechanism. Thereby it would be possible to 
compensate potential weak points in inhibition by 
combination with other compounds. 
 
PO-0991  
p53 and in vitro radiation response of fibroblasts from RT-
sensitive and -resistant patients 
C. Herskind
1Universitaetsmedizin Mannheim- Medical Faculty Mannheim- 
Heidelberg University, Department of Radiation Oncology, 
Mannheim, Germany 
1, O. Nuta2, N. Somaiah3, S. Boyle3, M.L.K. Chua4, 
L. Gothard3, K. Rothkamm5, J. Yarnold3 
2Public Health England, Centre for Radiation- Chemical and 
Environmental Hazards, Chilton, United Kingdom 
3Institute of Cancer Research, Division of Radiotherapy and 
Imaging, Sutton, United Kingdom 
4National Cancer Centre- Duke-NUS Graduate Medical School, 
Division of Radiation Oncology, Singapore, Singapore 
5Department of Radiotherapy and Radiation Oncology, 
University Medical Center Hamburg-Eppendorf, Hamburg, 
Germany 
 
Purpose or Objective: To test the association between the 
molecular and functional radiation response of fibroblasts in 
vitro and breast cancer patients' risk of late reaction after 
radiotherapy. 
 
Material and Methods: Fibroblast cultures were established 
by outgrowth from biopsies taken with informed consent from 
selected breast cancer patients with minimal (RT-resistant, 
n=15) or marked breast changes (RT-sensitive, n=19) after 
breast conserving therapy. The clinical risk of RT- sensitive 
patients was further ranked according to severity relative to 
external risk factors. Early-passage cultures were irradiated 
in vitro with 4Gy or sham irradiated. Molecular markers p53, 
p21/CDKN1A, p16/CDKN2A, α-sma, and Ki-67, were detected 
by immunofluorescence microscopy at 2h, 2 and 6 days after 
irradiation (IR). Plating efficiency (PE) and surviving fraction 
after 4 Gy (SF4) were determined by the colony formation 
assay. Non-parametric analysis of differences between 
fibroblasts from RT-sensitive and RT-resistant patients was 
performed with the Wilcoxon/Mann-Whitney test, and 
correlations using the Spearman's ρ rank correlation test. 
 
Results: The basal level of p53 without irradiation was 
significantly higher in fibroblast cultures from RT-sensitive 
relative to RT-resistant patients (P=0.02). p53 was 
upregulated 2h - 2 days after IR in all cells but decayed more 
slowly on day 6 in fibroblasts from RT-sensitive patients. 
Further, explorative analysis showed strong early 
upregulation of p53 2h after irradiation in fibroblasts from 
high-risk patients (P=0.002). RT sensitivity showed no 
significant correlation with p21/CDKN1A, p16/CDKN2A, a-
sma, and Ki-67, or functional endpoints, PE and SF4. 
However, proliferation activity (Ki-67 index) appeared to 
have a confounding influence on the effect of p53. Thus risk 
was correlated with basal levels of p53 (P<0.001) in 
unirradiated cultures with lower Ki-67 whereas it correlated 
with early upregulation at 2h (P<0.001) in cultures with 
higher Ki-67. Furthermore, correlations of p21/CDKN1A with 
p53 or p16/CDKN2A were markedly different in fibroblasts 
from RT sensitive and RT-resistant patients. 
 
Conclusion: In this cohort, patient selection was performed 
to enhance the contrast between RT-resistant and RT-
sensitive patients, including rare patients with severe late 
reaction. p53 levels in fibroblast cultures in vitro were 
significantly correlated with the risk of developing late breast 
changes after radiotherapy, and high-risk patients' fibroblasts 
showed strong early upregulation of p53 after irradiation 
which depended on the proliferation index. We suggest that a 
relation between p53 and the risk of late reaction exists in a 
subgroup of RT-sensitive patients, possibly via enhanced 
genetic instability and partial dysregulation of the DNA 
damage response. 
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Purpose or Objective: Rectal bleeding after radiation 
therapy (RT) for prostate cancer has been observed in up to 
40% of patients and it is mainly due to multiple rectal 
angiectasias developed after RT. Soon after the beginning of 
RT, there is an acute mucosal reaction that can evolve into a 
more severe condition with prominent vascular involvement, 
evidence of vasculitis, arteriolar thrombosis and subsequent 
ischemia and angiogenesis. Recently, attention to the role of 
hypoxia has contributed to the understanding of radiation-
induced late normal tissue response. Under hypoxic 
conditions, the diverse hypoxia-driven genes (e.g., VEGF) are 
regulated by a transcriptional factor, hypoxia-inducible 
factor-1 (HIF-1). In vivo and in vitro studies have shown that 
the HIF-1 expression increased soon after irradiation, 
reaching the highest level after 30 days and preceding the 
expression of VEGF.  
